Search

Displaying results 6401 - 6410 of 10000 in total
  1. Drug

    Forodesine

    go.drugbank.com/drugs/DB06185
    Investigational

    Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic

  2. Drug

    XC221

    go.drugbank.com/drugs/DB16503
    Investigational

    XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.

  3. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  4. Drug

    Tixocortol

    go.drugbank.com/drugs/DB09091
    ApprovedWithdrawn

    Tixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and to...

  5. Drug

    Recombinant Human Thrombopoietin

    go.drugbank.com/drugs/DB16364
    Investigational

    [A225691, A225696] This drug is used in the treatment of thrombocytopenia.

  6. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].

  7. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous le...

  8. Drug

    Darapladib

    go.drugbank.com/drugs/DB06311
    Investigational

  9. Drug

    Human growth hormone-releasing peptide 3

    go.drugbank.com/drugs/DB19227
    Investigational

    Human growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

  10. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.